Voglibose NEW
| Price | $30 | $46 | $66 |
| Package | 10mg | 25mg | 50mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Voglibose | CAS No.: 83480-29-9 |
| Purity: 98.00% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Voglibose |
| Description | Voglibose (Glustat), an N-substituted derivative of valiolamine, exhibits excellent inhibitory activity against α-glucosidases and action against hyperglycemia and various disorders caused by hyperglycemia. |
| In vitro | Voglibose can inhibit the intestinal α-glucosidases, which are responsible for the digestion of disaccharides such as maltose and sucrose, including maltase and sucrase. The Ki values of Voglibose for sucrase and maltase are about 106and 105 times smaller than the Km values for sucrose and maltose. [1] |
| In vivo | Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. Voglibose (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats. [2] Voglibose (0.001%) treatment increases GLP-1 secretion (Voglibose alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (Voglibose alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. Voglibose (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. Voglibose (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice. [3] Voglibose (0.001% and 0.005%) stimulates GLP-1 secretion in ob/ob mice, as evidenced by the 1.3- to 1.5-fold increase in plasma active plus inactive amidated GLP-1 levels. Voglibose (0.001% and 0.005%) decreases plasma DPP-4 activity unexpectedly by 40% to 51% in ob/ob mice, resulting from reduced plasma DPP-4 concentrations. Voglibose (0.001% and 0.005%) increases GLP-1 content by 1.5- to 1.6-fold and 1.4- to 1.6-fold in the lower intestine and colon, respectively, in ob/ob mice. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (374.14 mM), Sonication is recommended. H2O : 26.7 mg/mL (99.9 mM), Sonication is recommended. 10% DMSO+90% Saline : 10 mg/mL (37.41 mM), Solution. |
| Keywords | α-glucosidase | Voglibose | Inhibitor | inhibit | Glucosidase | AO-128 | AO128 |
| Inhibitors Related | Cedryl acetate | X-GAL | Hexylresorcinol | Conduritol B epoxide | Gcase activator 2 | Fucoidan | Miglitol | D-(-)-Quinic acid | (E)-3-(4-Methoxyphenyl)acrylic acid | Naringinase | Acarbose | 3-Butylidenephthalide |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Bioactive Compound Library | ReFRAME Related Library | Anti-Diabetic Compound Library | Anti-Obesity Compound Library | Saccharide and Glycoside Natural Product Library | Drug Repurposing Compound Library | Inhibitor Library | Metabolism Compound Library | Bioactive Compounds Library Max | NMPA-Approved Drug Library | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2025-05-21 | ||
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | ||
|
Moxin Chemicals
|
2025-03-13 | |||
|
Hebei Chuanghai Biotechnology Co., Ltd
|
2024-11-01 | |||
| $1.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2024-10-29 | ||
| $10.00 |
Ouhuang Engineering Materials (Hubei) Co., Ltd
|
2024-04-24 | ||
| $36.00 |
Shijiazhuang tongyang Import and Export Co., LTD
|
2021-08-12 | ||
| $15.00 |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
| $15700.00 |
Baoji Guokang Healthchem co.,ltd
|
2021-06-08 | ||
| $1050.00 |
VIP6Y
|
Baoji Guokang Healthchem Co., Ltd.
|
2021-06-08 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY